NVS 95.19 Novartis Ag $NVS Hit a 52 week high of 9
Post# of 54
Posted On: 11/20/2014 11:24:29 AM
NVS 95.19 Novartis Ag $NVS Hit a 52 week high of 95.52 Closing the day 09:45 at 95.19 -0.54 -0.56% With a day low of 95.15 and a total volume of 43,183.
NVS Recent Posts: http://investorshangout.com/Novartis-Ag-NVS-52134/
NVS Novartis Ag Recent Headline News
Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight Report
M2 - 1 hr 55 mins ago
Research and Markets (http://www.researchandmarkets.com/research/vk4t6m/non_hodgkin) has announced the addition of the "Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight" report to their offering. The market for Non Hodgkin Lymphoma has significant unmet medical necessities in terms of demand for innovative drugs and novel technologies. This is one of the major factors behind the market witnessing rapid growth in Non Hodgkin Lymphoma segment. Past few decades have witnessed an increased level of activity with regards to development of new identification systems and drug mechanisms. In recent years, there have been an increasing number of pharmaceutical companies focusing their efforts on developing better and highly effective therapeutics for Non Hodgkin Lymphoma which are likely to occupy major market share in coming years. The market of Non Hodgkin Lymphoma is expected to make steady growth in coming years due to raising incidences and introduction of new therapeutics by pharmaceutical companies in global market. This largely untapped market has yet to witness the products which would be able to prevent, cure this disease, decrease morbidity and mortality rates. Large amount of money invested in research and development has started to show positive effect on pharmaceutical industry. As a result, the introductions of large amount of therapeutic products in coming years are expected to increase global market size of Non Hodgkin Lymphoma therapeutics. Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight Report Highlight: - Global Non Hodgkin Lymphoma Market Overview - Mechanism of Non Hodgkin Lymphoma Therapeutics - Global Non Hodgkin Lymphoma Pipeline by Type, Phase & Company - Global Non Hodgkin Lymphoma Pipeline: 204 Drugs - Majority of the Drugs are in Phase-I: 54 Drugs - Marketed Drugs for Non Hodgkin Lymphoma: 30 Drugs - Patent Analysis by Country, Year & Compositions Key Topics Covered: 1. Introduction to Non Hodgkin Lymphoma 2. Mechanism of Non Hodgkin Lymphoma Therapeutics 3. Global Non Hodgkin Lymphoma Market Overview 4. Global Non Hodgkin Lymphoma Market Dynamics 5. Follicular Lymphoma Clinical Pipeline Insight by Phase, Indication, Company & Country 6. Non Hodgkin Lymphoma Clinical Pipeline Insight by Phase, Indication, Company & Country 7. B-Cell Lymphoma Clinical Pipeline Insight by Phase, Indication, Company & Country 8. Mantle Cell Lymphoma Clinical Pipeline Insight by Phase, Indication, Company & Country 9. Cutaneous T Cell Lymphoma Clinical Pipeline Insight by Phase, Indication, Company & Country 10. Cutaneous B-Cell Lymphoma Clinical Pipeline Insight by Phase, Indication, Company & Country 11. Diffuse Large B Cell Lymphoma Clinical Pipeline Insight by Phase, Indication, Company & Country 12. T Cell Lymphoma Clinical Pipeline Insight by Phase, Indication, Company & Country 13. Mycosis Fungoides Clinical Pipeline Insight by Phase, Indication, Company & Country 14. Peripheral T-cell lymphoma Clinical Pipeline Insight by Phase, Indication, Company & Country 15. Multiple Non Hodgkin Lymphoma Clinical Pipeline Insight by Phase, Indication, Company & Country 16. Competitive Landscape - Aryogen Biopharma - Biogen Idec - Biovest International - Chugai Pharmaceutical - Genetech - ImmunoGen - Johnson & Johnson - Novartis - Pfizer - Roche For more information visit http://www.researchandmarkets.com/research/vk...on_hodgkin
JNJ: 107.89 (-0.87), BIIB: 301.00 (-2.61), NVS: 95.54 (-0.19)
Research and Markets: Global Cushing's Syndrome Therapeutics Market 2015-2019: Key Vendors are Corcept Therapeutics, HRA Pharma and Novartis
Business Wire - Thu Nov 20, 7:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/b8gncx/global_cushings) has announced the addition of the "Global Cushing's Syndrome Therapeutics Market 2015-2019" report to their offering.
NVS: 95.54 (-0.19)
Global Cushing's Syndrome Therapeutics Market 2015-2019: Key Vendors are Corcept Therapeutics, HRA Pharma and Novartis
PR Newswire - Thu Nov 20, 7:07AM CST
Research and Markets has announced the addition of the "Global Cushing's Syndrome Therapeutics Market 2015-2019" report to their offering.
NVS: 95.54 (-0.19)
Global Active Pharmaceutical Ingredients Market - Trends & Forecast to 2020 for the $190 Billion Industry
M2 - Thu Nov 20, 6:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/sm7qx5/global_active) has announced the addition of the "Global Active Pharmaceutical Ingredients Market - Trends & Forecast to 2020" report to their offering. The global Active Pharmaceutical Ingredient market is expected to reach a market size approximately $190 billion by 2020, growing at a CAGR of more than 6.5% from 2014 to 2020 API market is mainly driven by the factors such as patent expiration of major drugs, increased generic medicine sales and high uptake of biologics. High Potential Active Pharmaceutical Ingredients (HPAPI) are also driving the API market growth globally as these compounds are very effective in treatment of diseases such as cancer, respiratory disorders and hormonal imbalances and HPAPI growth is mainly driven by its therapeutic applications in Oncology. Depending on the product type the API market is segmented into synthetic API, Biotech API, and HPAPI. Synthetic API commanded the largest share in 2013 and is growing at a steady pace, whereas the biotech API is expected to register the highest CAGR during the forecast period, strongly driven by the monoclonal antibodies and recombinant proteins. Depending on the applications the API market is categorized into oncology, cardiovascular and hematopoietic system, central nervous system, anti-infective, gastrointestinal, respiratory system, metabolic disorders, genito-urinary disorders, and others. Cardiovascular commanded the largest share of more than 40% in 2013 and is growing at a steady pace, whereas oncology is expected to register the highest CAGR during the forecast period. HPAPI commanded the largest share in the oncology application segment in 2013 and is growing at a highest CAGR in the anti-infectives segment. Scope of the Report Global API Market, by Synthesis: - Synthetic Chemical API - Branded/Innovative - Generic/Non-branded - Biotech API - Biologics - Biosimilars - Mammalian cell culture - Monoclonal antibodies - Recombinant proteins - Vaccines - Insulin analog - Growth hormone manufacturing - Interferon manufacturing - HPAPI Global API Market, by Business type: - Captive - Merchant Global API Market, by Therapeutic Applications: - Anti-infectives - Oncology - Cardiovascular and hematopoietic system - Central nervous system - Respiratory system - Gastrointestinal disorders - Hormone-related disorders - Metabolic disorders - Genitourinary disorders - Musculo-skeletal disorders - Others Companies Mentioned - Albemarle Corporation - Aurobindo - Boehringer Ingelheim GmbH - Cambrex Corporatio - Dr. Reddy's Lab - Lonza Group - Lupin - Novartis - Ranbaxy Laboratories - Teva Active Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/sm...bal_active
CBM: 22.93 (+0.21), ALB: 61.32 (-0.23), NVS: 95.54 (-0.19)
Playing Defense All Around The World
Eric Parnell, CFA - at Seeking Alpha - Thu Nov 20, 1:21AM CST
BTI: 116.50 (-0.43), BUD: 112.94 (+0.74), IPS: 39.38 (-0.02), IPU: 18.47 (-0.09), FXY: 82.44 (-0.07), XLU: 45.56 (-0.06), UUP: 23.28 (-0.02), DEO: 118.50 (+0.21), XLV: 68.14 (-0.15), XLP: 48.34 (-0.12), NVO: 44.43 (-0.31), AZN: 74.05 (-1.33), XLK: 41.52 (+0.12), FXE: 123.55 (-0.02), SNY: 46.94 (-1.15), NGG: 73.71 (-0.62), IRY: 48.30 (-0.49), XLE: 87.27 (+0.99), NVS: 95.54 (-0.19)
Piedmont Pharmaceuticals Prepares for Veterinary Companion Animal Product Launches
Marketwired - Wed Nov 19, 4:10PM CST
Piedmont Pharmaceuticals, LLC, an innovative pharmaceutical company focused on veterinary market pharmaceuticals, today announced its hiring of Mr. Stan Cruitt as Vice President of Marketing Services. "We couldn't be more pleased to have Stan join our team. His longstanding record of animal health pharmaceuticals launch success represents perfect timing as we at Piedmont are beginning to prepare for significant product launches," said Roland Johnson, founder, CEO and Board member of Piedmont Pharmaceuticals. "His record on market and product evaluation, product positioning and communications/marketing strategies stands against the very best in the industry. Stan was honored as one of the top marketers in the US by Advertising Age and Newsweek after one of his major product launches," adds Mr. Johnson.
NVS: 95.54 (-0.19)
Global Cervical Cancer Therapeutic Pipeline Review, H2 2014 - 35 Companies & 71 Drug Profiles
M2 - Wed Nov 19, 4:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/4p52hn/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - Nektar Therapeutics - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Amorfix Life Sciences Ltd. - MediGene AG - Nanotherapeutics, Inc. - Arbor Vita Corporation - Novartis AG - Chong Kun Dang Pharmaceutical Corp. - Taiho Pharmaceutical Co., Ltd. - Zeria Pharmaceutical Co Ltd - Genmab A/S - Advaxis, Inc. - 3SBio Inc. - Transgene SA - Antigen Express, Inc. - Shantha Biotechnics Limited - Bionor Pharma ASA - Azaya Therapeutics Incorporated - Merrimack Pharmaceuticals, Inc. - Genexine, Inc. - Genticel - Sirnaomics, Inc. - EyeGene, Inc. - Vaccibody AS - Wellstat Biologics Corporation - ISA Pharmaceuticals B.V. For more information visit http://www.researchandmarkets.com/research/4p...cal_cancer
MACK: 8.89 (+0.17), INO: 9.90 (+0.46), ADXS: 2.89 (+0.04), GSK: 46.41 (+0.16), NKTR: 13.99 (+0.23), NVS: 95.54 (-0.19)
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
ACT: 264.91 (-1.13), QLTI: 3.92 (-0.07), VRX: 142.98 (+0.51), AGN: 212.02 (-0.57), SHPG: 209.94 (+2.36), AUXL: 33.11 (+0.08), ABBV: 65.48 (-0.02), SNY: 46.94 (-1.15), ABT: 43.44 (+0.01), ENDP: 69.21 (+0.20), AKRX: 38.04 (-0.14), PFE: 30.43 (-0.01), INCY: 71.92 (+0.62), SLXP: 102.48 (-1.15), MYL: 55.63 (-0.05), AMGN: 164.02 (+1.38), LLY: 66.86 (-0.35), GSK: 46.41 (+0.16), BMY: 58.60 (-0.21), ACHN: 13.25 (+0.34), MRK: 59.20 (-0.44), AZN: 74.05 (-1.33), ICPT: 156.86 (+0.93), TEVA: 57.26 (+0.01), NVS: 95.54 (-0.19)
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
ACT: 264.91 (-1.13), QLTI: 3.92 (-0.07), VRX: 142.98 (+0.51), AGN: 212.02 (-0.57), SHPG: 209.94 (+2.36), AUXL: 33.11 (+0.08), ABBV: 65.48 (-0.02), SNY: 46.94 (-1.15), ABT: 43.44 (+0.01), ENDP: 69.21 (+0.20), AKRX: 38.04 (-0.14), PFE: 30.43 (-0.01), INCY: 71.92 (+0.62), SLXP: 102.48 (-1.15), MYL: 55.63 (-0.05), AMGN: 164.02 (+1.38), LLY: 66.86 (-0.35), GSK: 46.40 (+0.15), BMY: 58.60 (-0.21), ACHN: 13.25 (+0.34), MRK: 59.20 (-0.44), AZN: 74.05 (-1.33), ICPT: 156.86 (+0.93), TEVA: 57.26 (+0.01), NVS: 95.54 (-0.19)
Novartis Presents Data on Heart Failure Candidate LCZ696 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 3:44PM CST
Novartis (NVS) announced new data on pipeline candidate, LCZ696, from the phase III study, PARADIGM-HF.
AGN: 212.02 (-0.57), ABBV: 65.48 (-0.02), BMY: 58.60 (-0.21), NVS: 95.54 (-0.19)
Personal Dividend Growth Portfolio Update: November 2014
FinancialStorm - at Seeking Alpha - Tue Nov 18, 12:53PM CST
MDT: 71.53 (-0.23), NKSH: 30.00 (-0.56), DLR: 68.38 (-0.17), MBVT: 28.32 (-0.29), O: 45.85 (-0.05), INTC: 34.49 (+0.14), WEC: 48.59 (-0.06), BNS: 61.71 (+0.33), VTR: 68.28 (-0.24), COH: 36.03 (+0.59), MAT: 31.67 (+0.58), CMI: 143.81 (+0.67), DE: 85.65 (-0.68), MSFT: 48.31 (+0.09), WAG: 67.94 (+0.15), WFM: 48.17 (+0.39), NSC: 115.18 (+0.01), LLTC: 43.71 (+0.21), EMR: 64.51 (+0.36), VOD: 35.54 (-0.15), NEE: 103.01 (-0.70), BAX: 71.83 (-0.63), OHI: 37.20 (+0.20), VYM: 69.64 (+0.07), RBA: 25.68 (+0.13), TEVA: 57.26 (+0.01), PG: 88.65 (-0.08), VZ: 50.23 (-0.26), AFL: 58.94 (-0.12), NVS: 95.54 (-0.19)
Product and Pipeline Analysis of the Global Vaccines Market : Expected Launches in the Areas of Cancer and Allergies Will Drive Growth
PR Newswire - Tue Nov 18, 11:03AM CST
Executive Summary
MRK: 59.20 (-0.44), GSK: 46.40 (+0.15), NVS: 95.54 (-0.19)
Redbooth Raises $11M Series B and Signs OEM Deal for CA Technologies to License Its Real-Time Enterprise Collaboration Platform
PR Newswire - Tue Nov 18, 10:03AM CST
Redbooth, the enterprise real-time collaboration software company, today announced it has secured an $11 million Series B round, bringing total funding to $17.5 million. Investment was led by Menlo Park-based VC firm Altpoint Ventures, and Boston-based Avalon Ventures. Redbooth has gained significant traction with enterprise customers, including GE, Avis, US Airways, Dell, Warner Bros., Novartis, and more who seek the benefits of a single, integrated platform offering all applications required for teams to get work done. This includes a recent release of Redbooth enterprise chat which has contributed to a 6x increase in user engagement since its launch last month.
NVS: 95.54 (-0.19)
Cancer Diagnostics (Tumor Biomarker Tests, Imaging, Endoscopy and Biopsy) Market 2014 - 2020
M2 - Tue Nov 18, 9:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/cgz62c/cancer) has announced the addition of the "Cancer Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. Imaging, endoscopy, biopsy and tumor biomarker tests altogether comprise the global cancer diagnostics market. Imaging for cancer detection remains the largest segment in the cancer diagnostics market owing to its utilization in detection of almost every cancer type. MRI, PET, CT, mammography and ultrasound are the major imaging modalities, of which, CT scan and ultrasound imaging account for more than two-third of the total cancer imaging market. A tumor biomarker test is a segment in the cancer diagnostics market with highest research activity. Cancer biomarkers are increasingly being applied in cancer diagnostics; a highly sensitive and specific biomarker essentially helps in better diagnosis, monitoring and prognosis of cancer. Protein-based biomarkers such as alpha-fetoprotein (AFP), cancer embryonic antigen (CEA), prostate-specific antigen (PSA) are among the prominently used tumor biomarkers. The market for cancer diagnostics is majorly driven by demand from the patients affected with cancers of lung, breast, and colorectal cancer. Lung cancer is the most common cancer of all types and approximately 1.8 billion new cases of lung cancer were diagnosed in 2012. The increasing use of tobacco products in developing nations, particularly in BRICS countries, is contributing to the growing prevalence of lung cancer in the world. In 2013, the global lung cancer diagnostics market accounted for one-fourth of the global cancer diagnostics market revenue. In addition, the rising prevalence of breast cancer among women across the world, particularly in the Asia Pacific, is expected to drive the market for breast cancer diagnostics at the highest CAGR of 8.2% during the forecast period 2014 to 2020. The global cancer diagnostics market is led by players such as Abbott Laboratories, Ambry Genetics, AstraZeneca, bioMerieux, Eli Lilly and Co., Roche, GlaxoSmithKline plc, Novartis, and Pfizer. Scope of the Report Tumor Biomarker Tests: - PSA Tests - CTC Tests - AFP Tests - CA 19-9 - CA 125 - EGFR - HER2 - CEA - BRCA - KRAS - ALK Imaging - MRI Scan - PET Scan - CT Scan - Mammography - Ultrasound Endoscopy - Bronchoscopy - Colonoscopy - Sigmoidoscopy - Colposcopy - Others Biopsy - Bone Marrow Biopsy - Needle Biopsy - Endoscopic Biopsy Cancer Diagnostics Market, by Application: - Leukemia - Breast Cancer - Colorectal Cancer - Kidney - Liver - Lung - Ovarian - Pancreatic - Prostate Companies Mentioned - Abbott Laboratories, Inc. - Ambry Genetics - AstraZeneca plc - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Genoptix, Inc. - GlaxoSmithKline plc - Pfizer, Inc. - bioMeriux SA For more information visit http://www.researchandmarkets.com/research/cgz62c/cancer
ABT: 43.44 (+0.01), PFE: 30.43 (-0.01), AZN: 74.05 (-1.33), LLY: 66.87 (-0.34), GSK: 46.40 (+0.15), NVS: 95.54 (-0.19)
Global miRNA Research and Diagnostics Markets Report 2014
M2 - Tue Nov 18, 9:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/fjgcv3/mirna_research) has announced the addition of the "miRNA Research and Diagnostics Markets" report to their offering. This report considers the diagnostic promise of non-coding RNA molecules, with a particular focus on the microRNAs. miRNAs (MicroRNAs) are short, single stranded RNAs that regulate mRNA expression at the post-transcriptional level. These small bits of RNA, members of a class of non-translated molecules that donot produce protein, shut off gene transcription by base pairing with the target molecules. They are now recognized as pivotal regulators of gene expression; including development, proliferation, differentiation, and apoptosis and serving widespread functions as regulatory molecules in post-transcriptional gene silencing. As the report details, alarge number of companies, both small biotechs and big pharmaceutical companiesare committed to miRNA diagnostics. As part of its coverage of this topic, this report includes the following: - Overview of miRNAs - Positive Factors for miRNA Diagnostic Technologies - Negative Factors - miRNAs and Neurological Disorders - miRNA and Metastatic Brain Lesions - Prostate Cancer Screening and miRNAs - miRNAs and Resistance to Anti-Cancer Drugs - Theoretical Limitations - Discussion of Patent Issues - Interviews with Industry Experts - Market Estimate As part of its coverage, the miRNA offerings and products in developments in the following companies are profiled in detail: - Agilent Technologies - AMSBIO - Applied Biosystems - DiamiR, LLC - Dicerna - Eisai Biomarkers and Personalized Medicine - Diagnostics - Genomic Health Inc. - Gensignia - GlaxoSmithKline Discovery and Molecular Toxicology - Groove Biopharma (formerly Mirina) - Hologic-Gen Probe Inc. - Illumina, Inc. - Isis Pharmaceuticals - Mello Biotechnology Inc. - Microlin Bio - MiRagen Therapeutics - MiRNA Therapeutics - Novartis - Pacific Edge Biotechnology - Prolias Technologies - Regulus Therapeutics - Rosetta Genomics - Santaris Pharma A/S - Sirnaomics, Inc. - Somagenics - Diagnostics: Small RNA Assays and Biomarker Validation - Tekmira Pharmaceuticals Corporation - Thermadiag - Thermo Fisher Scientific, Inc. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Current State of the Art 4. Companies Developing microRNA Diagnostic Technologies 5. Market Estimates and Forecasts 6. Interviews with Industry Experts: Biomarkers 7. The Future of miRNA-Based Diagnostics For more information visit http://www.researchandmarkets.com/research/fj...a_research
ISIS: 51.38 (+1.32), A: 40.94 (+0.14), TKMR: 16.13 (+0.01), ILMN: 187.58 (-2.45), RGLS: 15.55 (-0.71), GSK: 46.40 (+0.15), HOLX: 26.22 (-0.07), GHDX: 31.96 (+0.10), NVS: 95.54 (-0.19)
PharmaSphere: Emerging Biotechnologies - Stem Cell Therapy
M2 - Tue Nov 18, 9:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/f3mqsf/pharmasphere) has announced the addition of the "PharmaSphere: Emerging Biotechnologies - Stem Cell Therapy" report to their offering. "PharmaSphere: Emerging Biotechnologies - Stem Cell Therapy", provides strategic analysis of the global stem cells industry. It discusses key development trends, regulatory requirements in various markets, recent deals activity and industry dynamic trends, as well as describes the operations strategy of these companies. Analyze and track the strategies that companies are using to enter and/or strengthen their position in the evolving stem cell industry, as well as efforts being made by innovator companies like Pfizer and Novartis to enter this market. Furthermore, it includes a geographical segmentation of various markets including the EU and US, as well as emerging markets such as China, India, SouthKorea, and Israel-providing in-depth analysis of these markets' regulatory framework, key domestic players and their stem cell pipelines, and strategic outlook. Throughout the report, Our analysts provide you with expert insight, expanding on each strategy and factor discussed, with the aim of providing you with the tools needed for making informed business decisions. Key Questions Answered - What are the key market drivers of the global stem cell industry? - Who are the top players involved in the development of stem cell therapies in developed as well as developing countries? - What are the main regulatory measures affecting the stem cell industry in the US, Europe, Japan, India, South Korea, China and Israel? - What are the major trends in stem cell clinical trials and profiles of key investigators? - What specific strategies are companies utilizing to combat some of the challenges currently facing the development of therapies in the global stem cell industry? Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Stem Cell Overview 4 Stem Cell Pipeline 5 Stem Cell Clinical Trials 6 Stem Cell Deals 7 Stem Cell Regulation 8 Company Landscape 9 Strategic Outlook 10 Appendix Companies Mentioned - Advanced Cell Technology - Anterogen - Asterias Biotherapeutics - Athersys - Bioheart - Bone Therapeutics - BrainStorm Cell Therapeutics - CHA Bio & Diostech - California Stem Cell - Capricor Therapeutics - Cardio3 BioSciences - Celgene - Cell Cure Neurosciences - Cellerant Therapeutics - Cellular Biomedicine Group - Cytomedix - Escape Therapeutics - Fate Therapeutics - Gamida Cell - Histocell - Orbsen Therapeutics - Pharmicell - Pluristem - Promethera Biosciences - ReNeuron - Reliance Life Sciences - Shenzhen Beike Biotechnology - StemCells - Stemedica - Stempeutics For more information visit http://www.researchandmarkets.com/research/f3...armasphere
FATE: 4.00 (+0.10), AST: 3.64 (-0.07), CBMG: 15.68 (+0.08), BCLI: 3.19 (-0.01), NVS: 95.54 (-0.19), CELGZ: 3.19 (-0.01)
Global Peanut Allergy Clinical Trials Review 2014 - Analysis of Top 7 Companies & 10 Institutues
M2 - Tue Nov 18, 8:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/qz9gnl/peanut_allergy) has announced the addition of the "Peanut Allergy Global Clinical Trials Review, H2, 2014" report to their offering. This report provides elemental information and data relating to the clinical trials on Peanut Allergy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Peanut Allergy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - DBV Technologies SA - F. Hoffmann-La Roche Ltd. - Novartis AG - Allergen Research Corporation - Immunomic Therapeutics, Inc. - HAL Allergy BV - Allertein Therapeutics, LLC Clinical Trial Overview of Top Institutes / Government - The National Institute of Allergy and Infectious Diseases - The University of North Carolina at Chapel Hill - University of North Carolina - Johns Hopkins University - Massachusetts General Hospital - Boston Children's Hospital - Baylor College of Medicine - McMaster University - Hamilton Health Sciences - Karolinska Institute For more information visit http://www.researchandmarkets.com/research/qz...ut_allergy
DBVT: 25.02 (-0.36), NVS: 95.54 (-0.19)
Novartis presents new data on heart failure drug candidate
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 6:47AM CST
NVS: 95.54 (-0.19)
Intellia Therapeutics Announces $15 Million in Funding to Develop Therapeutic Products Utilizing CRISPR-Cas9 Gene Editing Technology
Business Wire - Tue Nov 18, 6:00AM CST
Intellia Therapeutics, a new company formed to develop therapeutic products using CRISPR-Cas9 technology for gene editing and repair, announced today that it has closed a Series A investment round with $15 million in financing led by Atlas Venture and Novartis. Created by Atlas Venture and Caribou Biosciences, together with leading scientists who have pioneered and shaped the field of CRISPR biology, Intellia leverages exclusive access to one of the most comprehensive intellectual property portfolios covering the therapeutic application of this transformative technology.
NVS: 95.54 (-0.19)
NVS Recent Posts: http://investorshangout.com/Novartis-Ag-NVS-52134/
NVS Novartis Ag Recent Headline News
Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight Report
M2 - 1 hr 55 mins ago
Research and Markets (http://www.researchandmarkets.com/research/vk4t6m/non_hodgkin) has announced the addition of the "Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight" report to their offering. The market for Non Hodgkin Lymphoma has significant unmet medical necessities in terms of demand for innovative drugs and novel technologies. This is one of the major factors behind the market witnessing rapid growth in Non Hodgkin Lymphoma segment. Past few decades have witnessed an increased level of activity with regards to development of new identification systems and drug mechanisms. In recent years, there have been an increasing number of pharmaceutical companies focusing their efforts on developing better and highly effective therapeutics for Non Hodgkin Lymphoma which are likely to occupy major market share in coming years. The market of Non Hodgkin Lymphoma is expected to make steady growth in coming years due to raising incidences and introduction of new therapeutics by pharmaceutical companies in global market. This largely untapped market has yet to witness the products which would be able to prevent, cure this disease, decrease morbidity and mortality rates. Large amount of money invested in research and development has started to show positive effect on pharmaceutical industry. As a result, the introductions of large amount of therapeutic products in coming years are expected to increase global market size of Non Hodgkin Lymphoma therapeutics. Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight Report Highlight: - Global Non Hodgkin Lymphoma Market Overview - Mechanism of Non Hodgkin Lymphoma Therapeutics - Global Non Hodgkin Lymphoma Pipeline by Type, Phase & Company - Global Non Hodgkin Lymphoma Pipeline: 204 Drugs - Majority of the Drugs are in Phase-I: 54 Drugs - Marketed Drugs for Non Hodgkin Lymphoma: 30 Drugs - Patent Analysis by Country, Year & Compositions Key Topics Covered: 1. Introduction to Non Hodgkin Lymphoma 2. Mechanism of Non Hodgkin Lymphoma Therapeutics 3. Global Non Hodgkin Lymphoma Market Overview 4. Global Non Hodgkin Lymphoma Market Dynamics 5. Follicular Lymphoma Clinical Pipeline Insight by Phase, Indication, Company & Country 6. Non Hodgkin Lymphoma Clinical Pipeline Insight by Phase, Indication, Company & Country 7. B-Cell Lymphoma Clinical Pipeline Insight by Phase, Indication, Company & Country 8. Mantle Cell Lymphoma Clinical Pipeline Insight by Phase, Indication, Company & Country 9. Cutaneous T Cell Lymphoma Clinical Pipeline Insight by Phase, Indication, Company & Country 10. Cutaneous B-Cell Lymphoma Clinical Pipeline Insight by Phase, Indication, Company & Country 11. Diffuse Large B Cell Lymphoma Clinical Pipeline Insight by Phase, Indication, Company & Country 12. T Cell Lymphoma Clinical Pipeline Insight by Phase, Indication, Company & Country 13. Mycosis Fungoides Clinical Pipeline Insight by Phase, Indication, Company & Country 14. Peripheral T-cell lymphoma Clinical Pipeline Insight by Phase, Indication, Company & Country 15. Multiple Non Hodgkin Lymphoma Clinical Pipeline Insight by Phase, Indication, Company & Country 16. Competitive Landscape - Aryogen Biopharma - Biogen Idec - Biovest International - Chugai Pharmaceutical - Genetech - ImmunoGen - Johnson & Johnson - Novartis - Pfizer - Roche For more information visit http://www.researchandmarkets.com/research/vk...on_hodgkin
JNJ: 107.89 (-0.87), BIIB: 301.00 (-2.61), NVS: 95.54 (-0.19)
Research and Markets: Global Cushing's Syndrome Therapeutics Market 2015-2019: Key Vendors are Corcept Therapeutics, HRA Pharma and Novartis
Business Wire - Thu Nov 20, 7:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/b8gncx/global_cushings) has announced the addition of the "Global Cushing's Syndrome Therapeutics Market 2015-2019" report to their offering.
NVS: 95.54 (-0.19)
Global Cushing's Syndrome Therapeutics Market 2015-2019: Key Vendors are Corcept Therapeutics, HRA Pharma and Novartis
PR Newswire - Thu Nov 20, 7:07AM CST
Research and Markets has announced the addition of the "Global Cushing's Syndrome Therapeutics Market 2015-2019" report to their offering.
NVS: 95.54 (-0.19)
Global Active Pharmaceutical Ingredients Market - Trends & Forecast to 2020 for the $190 Billion Industry
M2 - Thu Nov 20, 6:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/sm7qx5/global_active) has announced the addition of the "Global Active Pharmaceutical Ingredients Market - Trends & Forecast to 2020" report to their offering. The global Active Pharmaceutical Ingredient market is expected to reach a market size approximately $190 billion by 2020, growing at a CAGR of more than 6.5% from 2014 to 2020 API market is mainly driven by the factors such as patent expiration of major drugs, increased generic medicine sales and high uptake of biologics. High Potential Active Pharmaceutical Ingredients (HPAPI) are also driving the API market growth globally as these compounds are very effective in treatment of diseases such as cancer, respiratory disorders and hormonal imbalances and HPAPI growth is mainly driven by its therapeutic applications in Oncology. Depending on the product type the API market is segmented into synthetic API, Biotech API, and HPAPI. Synthetic API commanded the largest share in 2013 and is growing at a steady pace, whereas the biotech API is expected to register the highest CAGR during the forecast period, strongly driven by the monoclonal antibodies and recombinant proteins. Depending on the applications the API market is categorized into oncology, cardiovascular and hematopoietic system, central nervous system, anti-infective, gastrointestinal, respiratory system, metabolic disorders, genito-urinary disorders, and others. Cardiovascular commanded the largest share of more than 40% in 2013 and is growing at a steady pace, whereas oncology is expected to register the highest CAGR during the forecast period. HPAPI commanded the largest share in the oncology application segment in 2013 and is growing at a highest CAGR in the anti-infectives segment. Scope of the Report Global API Market, by Synthesis: - Synthetic Chemical API - Branded/Innovative - Generic/Non-branded - Biotech API - Biologics - Biosimilars - Mammalian cell culture - Monoclonal antibodies - Recombinant proteins - Vaccines - Insulin analog - Growth hormone manufacturing - Interferon manufacturing - HPAPI Global API Market, by Business type: - Captive - Merchant Global API Market, by Therapeutic Applications: - Anti-infectives - Oncology - Cardiovascular and hematopoietic system - Central nervous system - Respiratory system - Gastrointestinal disorders - Hormone-related disorders - Metabolic disorders - Genitourinary disorders - Musculo-skeletal disorders - Others Companies Mentioned - Albemarle Corporation - Aurobindo - Boehringer Ingelheim GmbH - Cambrex Corporatio - Dr. Reddy's Lab - Lonza Group - Lupin - Novartis - Ranbaxy Laboratories - Teva Active Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/sm...bal_active
CBM: 22.93 (+0.21), ALB: 61.32 (-0.23), NVS: 95.54 (-0.19)
Playing Defense All Around The World
Eric Parnell, CFA - at Seeking Alpha - Thu Nov 20, 1:21AM CST
BTI: 116.50 (-0.43), BUD: 112.94 (+0.74), IPS: 39.38 (-0.02), IPU: 18.47 (-0.09), FXY: 82.44 (-0.07), XLU: 45.56 (-0.06), UUP: 23.28 (-0.02), DEO: 118.50 (+0.21), XLV: 68.14 (-0.15), XLP: 48.34 (-0.12), NVO: 44.43 (-0.31), AZN: 74.05 (-1.33), XLK: 41.52 (+0.12), FXE: 123.55 (-0.02), SNY: 46.94 (-1.15), NGG: 73.71 (-0.62), IRY: 48.30 (-0.49), XLE: 87.27 (+0.99), NVS: 95.54 (-0.19)
Piedmont Pharmaceuticals Prepares for Veterinary Companion Animal Product Launches
Marketwired - Wed Nov 19, 4:10PM CST
Piedmont Pharmaceuticals, LLC, an innovative pharmaceutical company focused on veterinary market pharmaceuticals, today announced its hiring of Mr. Stan Cruitt as Vice President of Marketing Services. "We couldn't be more pleased to have Stan join our team. His longstanding record of animal health pharmaceuticals launch success represents perfect timing as we at Piedmont are beginning to prepare for significant product launches," said Roland Johnson, founder, CEO and Board member of Piedmont Pharmaceuticals. "His record on market and product evaluation, product positioning and communications/marketing strategies stands against the very best in the industry. Stan was honored as one of the top marketers in the US by Advertising Age and Newsweek after one of his major product launches," adds Mr. Johnson.
NVS: 95.54 (-0.19)
Global Cervical Cancer Therapeutic Pipeline Review, H2 2014 - 35 Companies & 71 Drug Profiles
M2 - Wed Nov 19, 4:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/4p52hn/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - Nektar Therapeutics - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Amorfix Life Sciences Ltd. - MediGene AG - Nanotherapeutics, Inc. - Arbor Vita Corporation - Novartis AG - Chong Kun Dang Pharmaceutical Corp. - Taiho Pharmaceutical Co., Ltd. - Zeria Pharmaceutical Co Ltd - Genmab A/S - Advaxis, Inc. - 3SBio Inc. - Transgene SA - Antigen Express, Inc. - Shantha Biotechnics Limited - Bionor Pharma ASA - Azaya Therapeutics Incorporated - Merrimack Pharmaceuticals, Inc. - Genexine, Inc. - Genticel - Sirnaomics, Inc. - EyeGene, Inc. - Vaccibody AS - Wellstat Biologics Corporation - ISA Pharmaceuticals B.V. For more information visit http://www.researchandmarkets.com/research/4p...cal_cancer
MACK: 8.89 (+0.17), INO: 9.90 (+0.46), ADXS: 2.89 (+0.04), GSK: 46.41 (+0.16), NKTR: 13.99 (+0.23), NVS: 95.54 (-0.19)
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
ACT: 264.91 (-1.13), QLTI: 3.92 (-0.07), VRX: 142.98 (+0.51), AGN: 212.02 (-0.57), SHPG: 209.94 (+2.36), AUXL: 33.11 (+0.08), ABBV: 65.48 (-0.02), SNY: 46.94 (-1.15), ABT: 43.44 (+0.01), ENDP: 69.21 (+0.20), AKRX: 38.04 (-0.14), PFE: 30.43 (-0.01), INCY: 71.92 (+0.62), SLXP: 102.48 (-1.15), MYL: 55.63 (-0.05), AMGN: 164.02 (+1.38), LLY: 66.86 (-0.35), GSK: 46.41 (+0.16), BMY: 58.60 (-0.21), ACHN: 13.25 (+0.34), MRK: 59.20 (-0.44), AZN: 74.05 (-1.33), ICPT: 156.86 (+0.93), TEVA: 57.26 (+0.01), NVS: 95.54 (-0.19)
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
ACT: 264.91 (-1.13), QLTI: 3.92 (-0.07), VRX: 142.98 (+0.51), AGN: 212.02 (-0.57), SHPG: 209.94 (+2.36), AUXL: 33.11 (+0.08), ABBV: 65.48 (-0.02), SNY: 46.94 (-1.15), ABT: 43.44 (+0.01), ENDP: 69.21 (+0.20), AKRX: 38.04 (-0.14), PFE: 30.43 (-0.01), INCY: 71.92 (+0.62), SLXP: 102.48 (-1.15), MYL: 55.63 (-0.05), AMGN: 164.02 (+1.38), LLY: 66.86 (-0.35), GSK: 46.40 (+0.15), BMY: 58.60 (-0.21), ACHN: 13.25 (+0.34), MRK: 59.20 (-0.44), AZN: 74.05 (-1.33), ICPT: 156.86 (+0.93), TEVA: 57.26 (+0.01), NVS: 95.54 (-0.19)
Novartis Presents Data on Heart Failure Candidate LCZ696 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 3:44PM CST
Novartis (NVS) announced new data on pipeline candidate, LCZ696, from the phase III study, PARADIGM-HF.
AGN: 212.02 (-0.57), ABBV: 65.48 (-0.02), BMY: 58.60 (-0.21), NVS: 95.54 (-0.19)
Personal Dividend Growth Portfolio Update: November 2014
FinancialStorm - at Seeking Alpha - Tue Nov 18, 12:53PM CST
MDT: 71.53 (-0.23), NKSH: 30.00 (-0.56), DLR: 68.38 (-0.17), MBVT: 28.32 (-0.29), O: 45.85 (-0.05), INTC: 34.49 (+0.14), WEC: 48.59 (-0.06), BNS: 61.71 (+0.33), VTR: 68.28 (-0.24), COH: 36.03 (+0.59), MAT: 31.67 (+0.58), CMI: 143.81 (+0.67), DE: 85.65 (-0.68), MSFT: 48.31 (+0.09), WAG: 67.94 (+0.15), WFM: 48.17 (+0.39), NSC: 115.18 (+0.01), LLTC: 43.71 (+0.21), EMR: 64.51 (+0.36), VOD: 35.54 (-0.15), NEE: 103.01 (-0.70), BAX: 71.83 (-0.63), OHI: 37.20 (+0.20), VYM: 69.64 (+0.07), RBA: 25.68 (+0.13), TEVA: 57.26 (+0.01), PG: 88.65 (-0.08), VZ: 50.23 (-0.26), AFL: 58.94 (-0.12), NVS: 95.54 (-0.19)
Product and Pipeline Analysis of the Global Vaccines Market : Expected Launches in the Areas of Cancer and Allergies Will Drive Growth
PR Newswire - Tue Nov 18, 11:03AM CST
Executive Summary
MRK: 59.20 (-0.44), GSK: 46.40 (+0.15), NVS: 95.54 (-0.19)
Redbooth Raises $11M Series B and Signs OEM Deal for CA Technologies to License Its Real-Time Enterprise Collaboration Platform
PR Newswire - Tue Nov 18, 10:03AM CST
Redbooth, the enterprise real-time collaboration software company, today announced it has secured an $11 million Series B round, bringing total funding to $17.5 million. Investment was led by Menlo Park-based VC firm Altpoint Ventures, and Boston-based Avalon Ventures. Redbooth has gained significant traction with enterprise customers, including GE, Avis, US Airways, Dell, Warner Bros., Novartis, and more who seek the benefits of a single, integrated platform offering all applications required for teams to get work done. This includes a recent release of Redbooth enterprise chat which has contributed to a 6x increase in user engagement since its launch last month.
NVS: 95.54 (-0.19)
Cancer Diagnostics (Tumor Biomarker Tests, Imaging, Endoscopy and Biopsy) Market 2014 - 2020
M2 - Tue Nov 18, 9:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/cgz62c/cancer) has announced the addition of the "Cancer Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. Imaging, endoscopy, biopsy and tumor biomarker tests altogether comprise the global cancer diagnostics market. Imaging for cancer detection remains the largest segment in the cancer diagnostics market owing to its utilization in detection of almost every cancer type. MRI, PET, CT, mammography and ultrasound are the major imaging modalities, of which, CT scan and ultrasound imaging account for more than two-third of the total cancer imaging market. A tumor biomarker test is a segment in the cancer diagnostics market with highest research activity. Cancer biomarkers are increasingly being applied in cancer diagnostics; a highly sensitive and specific biomarker essentially helps in better diagnosis, monitoring and prognosis of cancer. Protein-based biomarkers such as alpha-fetoprotein (AFP), cancer embryonic antigen (CEA), prostate-specific antigen (PSA) are among the prominently used tumor biomarkers. The market for cancer diagnostics is majorly driven by demand from the patients affected with cancers of lung, breast, and colorectal cancer. Lung cancer is the most common cancer of all types and approximately 1.8 billion new cases of lung cancer were diagnosed in 2012. The increasing use of tobacco products in developing nations, particularly in BRICS countries, is contributing to the growing prevalence of lung cancer in the world. In 2013, the global lung cancer diagnostics market accounted for one-fourth of the global cancer diagnostics market revenue. In addition, the rising prevalence of breast cancer among women across the world, particularly in the Asia Pacific, is expected to drive the market for breast cancer diagnostics at the highest CAGR of 8.2% during the forecast period 2014 to 2020. The global cancer diagnostics market is led by players such as Abbott Laboratories, Ambry Genetics, AstraZeneca, bioMerieux, Eli Lilly and Co., Roche, GlaxoSmithKline plc, Novartis, and Pfizer. Scope of the Report Tumor Biomarker Tests: - PSA Tests - CTC Tests - AFP Tests - CA 19-9 - CA 125 - EGFR - HER2 - CEA - BRCA - KRAS - ALK Imaging - MRI Scan - PET Scan - CT Scan - Mammography - Ultrasound Endoscopy - Bronchoscopy - Colonoscopy - Sigmoidoscopy - Colposcopy - Others Biopsy - Bone Marrow Biopsy - Needle Biopsy - Endoscopic Biopsy Cancer Diagnostics Market, by Application: - Leukemia - Breast Cancer - Colorectal Cancer - Kidney - Liver - Lung - Ovarian - Pancreatic - Prostate Companies Mentioned - Abbott Laboratories, Inc. - Ambry Genetics - AstraZeneca plc - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Genoptix, Inc. - GlaxoSmithKline plc - Pfizer, Inc. - bioMeriux SA For more information visit http://www.researchandmarkets.com/research/cgz62c/cancer
ABT: 43.44 (+0.01), PFE: 30.43 (-0.01), AZN: 74.05 (-1.33), LLY: 66.87 (-0.34), GSK: 46.40 (+0.15), NVS: 95.54 (-0.19)
Global miRNA Research and Diagnostics Markets Report 2014
M2 - Tue Nov 18, 9:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/fjgcv3/mirna_research) has announced the addition of the "miRNA Research and Diagnostics Markets" report to their offering. This report considers the diagnostic promise of non-coding RNA molecules, with a particular focus on the microRNAs. miRNAs (MicroRNAs) are short, single stranded RNAs that regulate mRNA expression at the post-transcriptional level. These small bits of RNA, members of a class of non-translated molecules that donot produce protein, shut off gene transcription by base pairing with the target molecules. They are now recognized as pivotal regulators of gene expression; including development, proliferation, differentiation, and apoptosis and serving widespread functions as regulatory molecules in post-transcriptional gene silencing. As the report details, alarge number of companies, both small biotechs and big pharmaceutical companiesare committed to miRNA diagnostics. As part of its coverage of this topic, this report includes the following: - Overview of miRNAs - Positive Factors for miRNA Diagnostic Technologies - Negative Factors - miRNAs and Neurological Disorders - miRNA and Metastatic Brain Lesions - Prostate Cancer Screening and miRNAs - miRNAs and Resistance to Anti-Cancer Drugs - Theoretical Limitations - Discussion of Patent Issues - Interviews with Industry Experts - Market Estimate As part of its coverage, the miRNA offerings and products in developments in the following companies are profiled in detail: - Agilent Technologies - AMSBIO - Applied Biosystems - DiamiR, LLC - Dicerna - Eisai Biomarkers and Personalized Medicine - Diagnostics - Genomic Health Inc. - Gensignia - GlaxoSmithKline Discovery and Molecular Toxicology - Groove Biopharma (formerly Mirina) - Hologic-Gen Probe Inc. - Illumina, Inc. - Isis Pharmaceuticals - Mello Biotechnology Inc. - Microlin Bio - MiRagen Therapeutics - MiRNA Therapeutics - Novartis - Pacific Edge Biotechnology - Prolias Technologies - Regulus Therapeutics - Rosetta Genomics - Santaris Pharma A/S - Sirnaomics, Inc. - Somagenics - Diagnostics: Small RNA Assays and Biomarker Validation - Tekmira Pharmaceuticals Corporation - Thermadiag - Thermo Fisher Scientific, Inc. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Current State of the Art 4. Companies Developing microRNA Diagnostic Technologies 5. Market Estimates and Forecasts 6. Interviews with Industry Experts: Biomarkers 7. The Future of miRNA-Based Diagnostics For more information visit http://www.researchandmarkets.com/research/fj...a_research
ISIS: 51.38 (+1.32), A: 40.94 (+0.14), TKMR: 16.13 (+0.01), ILMN: 187.58 (-2.45), RGLS: 15.55 (-0.71), GSK: 46.40 (+0.15), HOLX: 26.22 (-0.07), GHDX: 31.96 (+0.10), NVS: 95.54 (-0.19)
PharmaSphere: Emerging Biotechnologies - Stem Cell Therapy
M2 - Tue Nov 18, 9:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/f3mqsf/pharmasphere) has announced the addition of the "PharmaSphere: Emerging Biotechnologies - Stem Cell Therapy" report to their offering. "PharmaSphere: Emerging Biotechnologies - Stem Cell Therapy", provides strategic analysis of the global stem cells industry. It discusses key development trends, regulatory requirements in various markets, recent deals activity and industry dynamic trends, as well as describes the operations strategy of these companies. Analyze and track the strategies that companies are using to enter and/or strengthen their position in the evolving stem cell industry, as well as efforts being made by innovator companies like Pfizer and Novartis to enter this market. Furthermore, it includes a geographical segmentation of various markets including the EU and US, as well as emerging markets such as China, India, SouthKorea, and Israel-providing in-depth analysis of these markets' regulatory framework, key domestic players and their stem cell pipelines, and strategic outlook. Throughout the report, Our analysts provide you with expert insight, expanding on each strategy and factor discussed, with the aim of providing you with the tools needed for making informed business decisions. Key Questions Answered - What are the key market drivers of the global stem cell industry? - Who are the top players involved in the development of stem cell therapies in developed as well as developing countries? - What are the main regulatory measures affecting the stem cell industry in the US, Europe, Japan, India, South Korea, China and Israel? - What are the major trends in stem cell clinical trials and profiles of key investigators? - What specific strategies are companies utilizing to combat some of the challenges currently facing the development of therapies in the global stem cell industry? Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Stem Cell Overview 4 Stem Cell Pipeline 5 Stem Cell Clinical Trials 6 Stem Cell Deals 7 Stem Cell Regulation 8 Company Landscape 9 Strategic Outlook 10 Appendix Companies Mentioned - Advanced Cell Technology - Anterogen - Asterias Biotherapeutics - Athersys - Bioheart - Bone Therapeutics - BrainStorm Cell Therapeutics - CHA Bio & Diostech - California Stem Cell - Capricor Therapeutics - Cardio3 BioSciences - Celgene - Cell Cure Neurosciences - Cellerant Therapeutics - Cellular Biomedicine Group - Cytomedix - Escape Therapeutics - Fate Therapeutics - Gamida Cell - Histocell - Orbsen Therapeutics - Pharmicell - Pluristem - Promethera Biosciences - ReNeuron - Reliance Life Sciences - Shenzhen Beike Biotechnology - StemCells - Stemedica - Stempeutics For more information visit http://www.researchandmarkets.com/research/f3...armasphere
FATE: 4.00 (+0.10), AST: 3.64 (-0.07), CBMG: 15.68 (+0.08), BCLI: 3.19 (-0.01), NVS: 95.54 (-0.19), CELGZ: 3.19 (-0.01)
Global Peanut Allergy Clinical Trials Review 2014 - Analysis of Top 7 Companies & 10 Institutues
M2 - Tue Nov 18, 8:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/qz9gnl/peanut_allergy) has announced the addition of the "Peanut Allergy Global Clinical Trials Review, H2, 2014" report to their offering. This report provides elemental information and data relating to the clinical trials on Peanut Allergy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Peanut Allergy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - DBV Technologies SA - F. Hoffmann-La Roche Ltd. - Novartis AG - Allergen Research Corporation - Immunomic Therapeutics, Inc. - HAL Allergy BV - Allertein Therapeutics, LLC Clinical Trial Overview of Top Institutes / Government - The National Institute of Allergy and Infectious Diseases - The University of North Carolina at Chapel Hill - University of North Carolina - Johns Hopkins University - Massachusetts General Hospital - Boston Children's Hospital - Baylor College of Medicine - McMaster University - Hamilton Health Sciences - Karolinska Institute For more information visit http://www.researchandmarkets.com/research/qz...ut_allergy
DBVT: 25.02 (-0.36), NVS: 95.54 (-0.19)
Novartis presents new data on heart failure drug candidate
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 6:47AM CST
NVS: 95.54 (-0.19)
Intellia Therapeutics Announces $15 Million in Funding to Develop Therapeutic Products Utilizing CRISPR-Cas9 Gene Editing Technology
Business Wire - Tue Nov 18, 6:00AM CST
Intellia Therapeutics, a new company formed to develop therapeutic products using CRISPR-Cas9 technology for gene editing and repair, announced today that it has closed a Series A investment round with $15 million in financing led by Atlas Venture and Novartis. Created by Atlas Venture and Caribou Biosciences, together with leading scientists who have pioneered and shaped the field of CRISPR biology, Intellia leverages exclusive access to one of the most comprehensive intellectual property portfolios covering the therapeutic application of this transformative technology.
NVS: 95.54 (-0.19)
(0)
(0)Novartis Ag (NVS) Stock Research Links
Scroll down for more posts ▼